Aduro’s proprietary technologies (STING and APRIL Pathways) have the potential to transform the current immunotherapy landscape.

Aduro is developing novel therapies that are designed to induce highly targeted, potent and sustained immune responses against a variety of diseases. Through our STING and APRIL Pathway technologies, we are poised to fulfill our mission to stay at the forefront of discovery, development and commercialization of immunotherapies, alone or in combination, that have the potential to make transformative advances in the treatment of challenging diseases.

In addition, Aduro has established significant collaboration agreements with leading pharmaceutical and research institutions for its technologies, further validating the strength and depth of Aduro’s capabilities.

STING Pathway

APRIL Pathway